{
  "symbol": "NBTX",
  "company_name": "Nanobiotix S.A. ADR",
  "ir_website": "https://ir.nanobiotix.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.nanobiotix.com/news-events/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Press Releases\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\nYear All202420232022202120202019201820172016201520142013201220112010\n\n2024\n\nNov 13 2024\n\n[Voting Rights and Shares Capital of the Company](/news-releases/news-release-details/voting-rights-and-shares-capital-company-19)\n\nIn accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Paris, France, November 13, 2024 Market: Euronext Paris / Nasdaq Euronext \n\n[Read More](/news-releases/news-release-details/voting-rights-and-shares-capital-company-19)\n\n[PDF Version](/node/14696/pdf)\n\nNov 12 2024\n\n[NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms ](/news-releases/news-release-details/nanobiotix-provides-third-quarter-2024-update-and-progress)\n\nTransferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission Added expert industry leaders to Supervisory Board, further strengthening support for the Company’s long-term growth strategy NBTXR3 program \n\n[Read More](/news-releases/news-release-details/nanobiotix-provides-third-quarter-2024-update-and-progress)\n\n[PDF Version](/node/14681/pdf)\n\nOct 31 2024\n\n[NANOBIOTIX to Participate in Multiple Investor Conferences in November](/news-releases/news-release-details/nanobiotix-participate-multiple-investor-conferences-november)\n\n~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a \n\n[Read More](/news-releases/news-release-details/nanobiotix-participate-multiple-investor-conferences-november)\n\n[PDF Version](/node/14651/pdf)\n\nOct 11 2024\n\n[Voting Rights and Shares Capital of the Company](/news-releases/news-release-details/voting-rights-and-shares-capital-company-18)\n\nIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Paris, France, October 11, 2024 Market: Euronext Paris / Nasdaq Euronext \n\n[Read More](/news-releases/news-release-details/voting-rights-and-shares-capital-company-18)\n\n[PDF Version](/node/14576/pdf)\n\nSep 18 2024\n\n[NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results](/news-releases/news-release-details/nanobiotix-provides-business-update-and-reports-half-year-2024)\n\nRT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapy Several clinical milestones expected over the next 12-18 months \n\n[Read More](/news-releases/news-release-details/nanobiotix-provides-business-update-and-reports-half-year-2024)\n\n[PDF Version](/node/14471/pdf)\n\nSep 04 2024\n\n[NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth](/news-releases/news-release-details/nanobiotix-announces-two-key-supervisory-board-additions)\n\nDr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boards Ms. Anat Naschitz, proven life science investor and entrepreneur; co-founder of OrbiMed Israel PARIS and CAMBRIDGE, Mass., Sept. \n\n[Read More](/news-releases/news-release-details/nanobiotix-announces-two-key-supervisory-board-additions)\n\n[PDF Version](/node/14396/pdf)\n\nSep 03 2024\n\n[Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference](/news-releases/news-release-details/nanobiotix-present-hc-wainwright-26th-annual-global-investment)\n\nPARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company \n\n[Read More](/news-releases/news-release-details/nanobiotix-present-hc-wainwright-26th-annual-global-investment)\n\n[PDF Version](/node/14381/pdf)\n\nAug 08 2024\n\n[Voting Rights and Shares Capital of the Company](/news-releases/news-release-details/voting-rights-and-shares-capital-company-17)\n\nIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Paris, France, August 8, 2024 Market: Euronext Paris / Nasdaq Euronext \n\n[Read More](/news-releases/news-release-details/voting-rights-and-shares-capital-company-17)\n\n[PDF Version](/node/14301/pdf)\n\nJul 09 2024\n\n[Voting Rights and Shares Capital of the Company](/news-releases/news-release-details/voting-rights-and-shares-capital-company-16)\n\nIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, July 09, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: \n\n[Read More](/news-releases/news-release-details/voting-rights-and-shares-capital-company-16)\n\n[PDF Version](/node/14181/pdf)\n\nJun 12 2024\n\n[NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024](/news-releases/news-release-details/nanobiotix-host-virtual-kol-event-discussing-potential-nbtxr3)\n\nPARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will \n\n[Read More](/news-releases/news-release-details/nanobiotix-host-virtual-kol-event-discussing-potential-nbtxr3)\n\n[PDF Version](/node/14121/pdf)\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        },
        {
          "title": "Events & Presentations",
          "url": "https://ir.nanobiotix.com/news-events/events-and-presentations",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Events & Presentations\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\n## Past Events\n\nYear All2024202320222021\n\n2024\n\nNov  20  2024  at 8:00 AM EST \n\nNov  20  2024  at 8:00 AM EST \n\n[Jefferies London Healthcare Conference](/events/event-details/jefferies-london-healthcare-conference-1)\n\n[Webcast](https://wsw.com/webcast/jeff315/nbtx/1867824)\n\n[Read More](/events/event-details/jefferies-london-healthcare-conference-1)\n\nNov  18  2024  at 4:45 PM EST \n\nNov  18  2024  at 4:45 PM EST \n\n[Stifel Healthcare Conference](/events/event-details/stifel-healthcare-conference)\n\n[Webcast](https://wsw.com/webcast/stifel96/nbtx/2121576)\n\n[Read More](/events/event-details/stifel-healthcare-conference)\n\nNov  11  2024  at 4:00 PM EST \n\nNov  11  2024  at 4:00 PM EST \n\n[Guggenheim’s Inaugural Healthcare Innovation Conference](/events/event-details/guggenheims-inaugural-healthcare-innovation-conference)\n\n[Webcast](https://wsw.com/webcast/guggen/nbtx/1963308)\n\n[Read More](/events/event-details/guggenheims-inaugural-healthcare-innovation-conference)\n\nSep  11  2024  at 9:30 AM EDT \n\nSep  11  2024  at 9:30 AM EDT \n\n[H.C. Wainwright 26th Annual Global Investment Conference](/events/event-details/hc-wainwright-26th-annual-global-investment-conference)\n\n[Webcast](https://journey.ct.events/view/46e97538-30c8-4f5a-b066-bd94a599bc71)\n\n[Read More](/events/event-details/hc-wainwright-26th-annual-global-investment-conference)\n\nJun  18  2024  at 9:00 AM EDT \n\nJun  18  2024  at 9:00 AM EDT \n\n[NBTXR3 in Head and Neck Cancer KOL Call 2024](/events/event-details/kol-call-2024)\n\n[Webcast](https://nanobiotix-kol-call-nbtxr3-immune-oncology.open-exchange.net/)\n\n[Read More](/events/event-details/kol-call-2024)\n\n## Latest Presentation\n\nCorporate Presentation\n\n[Download](/static-files/d968a49d-0b57-422f-97ab-43906f6503d7)\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.nanobiotix.com/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# SEC Filings\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year All202420232022202120202019\n\nAll\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort By Filing Date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort By Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort By Form\") | View  \n---|---|---|---  \nNov 13, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-006345) |  [View HTML](/node/14701/html) [0001171843-24-006345.pdf](/static-files/ec8de8fe-b6a4-4050-89b1-8f9c84e79f1c) [0001171843-24-006345.rtf](/static-files/232b71bc-e0d1-410a-a434-c5ed7b111c5d) [0001171843-24-006345.xls](/static-files/f6e57257-84fb-4547-b718-fa772f986631)  \nNov 12, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-006193) |  [View HTML](/node/14686/html) [0001171843-24-006193.pdf](/static-files/bfe45a71-b3d6-4abd-a7af-e3af40d068a8) [0001171843-24-006193.rtf](/static-files/9d5094fb-14fb-40a5-9fa1-06ea444f1fdc) [0001171843-24-006193.xls](/static-files/91f32e17-dd66-4ce6-801f-d2207df0b67e)  \nOct 31, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-005914) |  [View HTML](/node/14656/html) [0001171843-24-005914.pdf](/static-files/2804e3ef-d38b-4efa-9949-e37867b2c127) [0001171843-24-005914.rtf](/static-files/32e8e186-3f0c-4a23-8a3e-f93a09a44d74) [0001171843-24-005914.xls](/static-files/e7277bd0-e468-479e-bfff-d18adc728720)  \nOct 11, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-005598) |  [View HTML](/node/14581/html) [0001171843-24-005598.pdf](/static-files/ac268224-54d1-4e92-8815-d92c366ddf17) [0001171843-24-005598.rtf](/static-files/cb9a0ecb-a58a-42da-816d-888466748f95) [0001171843-24-005598.xls](/static-files/ecd8886a-3b99-478e-b044-1b319e7b7544)  \nSep 18, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-005248) |  [View HTML](/node/14476/html) [0001171843-24-005248.pdf](/static-files/40687d77-96e0-4c69-966e-1acd120b6b45) [0001171843-24-005248.rtf](/static-files/605dd205-294c-40c6-a23e-a35ce1aabbda) [0001171843-24-005248.xls](/static-files/ece109ce-94cf-44c9-826e-ace944008b49)  \nSep 18, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001760854-24-000010) |  [View HTML](/node/14481/html) [0001760854-24-000010.pdf](/static-files/4ecfdefb-4abc-4271-beae-7f115caf8f6c) [0001760854-24-000010.rtf](/static-files/9d9df8d3-3030-4692-accf-7366e82de647) [0001760854-24-000010.xls](/static-files/bc2439d7-aa19-44ba-8a28-7fda69c9860d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/6-k/0001760854-24-000010)  \nSep 04, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-005064) |  [View HTML](/node/14406/html) [0001171843-24-005064.pdf](/static-files/b4a7f70d-e7a2-4bed-8aa1-8c4552e9505e) [0001171843-24-005064.rtf](/static-files/0b75285a-afbd-431c-86b7-21edbc7799ad) [0001171843-24-005064.xls](/static-files/7fa60b84-a9e1-42ee-8295-14e4deddf7ff)  \nSep 03, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-005027) |  [View HTML](/node/14386/html) [0001171843-24-005027.pdf](/static-files/c437fb4c-5756-4e59-9df8-5581ea3073ce) [0001171843-24-005027.rtf](/static-files/697706dd-4b2c-4d88-84c6-f86e61d6cac1) [0001171843-24-005027.xls](/static-files/3ddee9fd-0fc8-4a3e-a9df-2263b91c1af6)  \nAug 08, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-004608) |  [View HTML](/node/14311/html) [0001171843-24-004608.pdf](/static-files/3d16d001-d74b-4ac6-a59c-91ced9400288) [0001171843-24-004608.rtf](/static-files/f0303076-efe3-413f-b952-0bdc79bd4828) [0001171843-24-004608.xls](/static-files/f80b3366-1928-4278-903e-31923f999709)  \nJul 09, 2024 |  Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |  [6-K](/sec-filings/sec-filing/6-k/0001171843-24-003862) |  [View HTML](/node/14186/html) [0001171843-24-003862.pdf](/static-files/4dd847c1-3e38-49ea-ac8c-0fa829509b78) [0001171843-24-003862.rtf](/static-files/29d4f288-b123-4080-86e6-549659861e40) [0001171843-24-003862.xls](/static-files/dc95b956-f9a3-41ea-8d45-6bc7aaf29a12)  \n  \nDisplaying 1 - 10 of 207 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n\n![Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=e81fc3ad-8c8d-42f5-ae2d-a2b6fa77dc61)\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.nanobiotix.com/financial-information/annual-reports",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Annual Reports\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\n![Universal Registration Document 2023](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2024/04/24/17-24-49/AR%202023.png?itok=V4124y6g)\n\n[Universal Registration Document 2023](/static-files/95be6eda-5c95-4d53-b3e5-59b50949e8b5 \"Nanobiotix - AMF - URD 2023 - vdef.pdf\") 14.8 MB\n\n[FORM 20-F/A](/static-files/73e67cc7-ab73-44ca-9abe-137be2762889 \"Nanobiotix - SEC - 20-F 2023 - vdef.pdf\") 9.7 MB\n\n[Letter from the Chairman](/static-files/c46f08c5-713c-4392-8fe3-b2e9eb0ea278 \"Nanobiotix - 20-F 2023 - Letter from the Chair - FINAL.pdf\") 176 KB\n\n![Universal Registration Document 2022](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2023/04/24/18-50-12/AR%202022.png?itok=D5F9VsQ-)\n\n[Universal Registration Document 2022](/static-files/2b36ab88-a00d-49bd-86ae-2e94d5b784b2 \"Nanobiotix - AMF - URD 2022 PDF.pdf\") 11 MB\n\n[FORM 20-F/A](/static-files/1a9b5228-b5c7-4292-9a1c-aca30fa9c3c3 \"Nanobiotix - SEC - 20-F 2022 PDF.pdf\") 8.4 MB\n\n![Universal Registration Document 2021](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/04/08/17-29-21/capture.png?itok=CQxn9VLO)\n\n[Universal Registration Document 2021](/static-files/a22f186b-699d-4bc7-a88d-d221d5c28907 \"Nanobiotix - AMF - URD 2021.pdf\") 6 MB\n\n[FORM 20-F/A](/static-files/cc5c01f9-988e-47d4-8a09-73d294789bb0 \"Nanobiotix - SEC - 20-F 2021.pdf\") 3.4 MB\n\n![Universal Registration Document 2020](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/03/28/2-52-09/2020-report-cover.jpg?itok=JcOYctUl)\n\n[Universal Registration Document 2020](/static-files/c39790ce-aada-4621-844a-a1dd7ddf9f75 \"2021-027200.pdf\") 5.8 MB\n\n[FORM 20-F/A](/static-files/2458d9d2-eb51-4ae1-b876-8c4a37048610 \"SEC-FILING-FY20-2021-04-08-00-10-2.pdf\") 3.5 MB\n\n![](/sites/g/files/knoqqb86031/themes/site/client_site/dist/images/default-cover.jpg)\n\n[Form F-1 REGISTRATION STATEMENT](/static-files/afda0237-3872-4d90-b718-91d5aa8b6695 \"nt10009390x7_f1_2020.pdf\") 6.7 MB\n\n![Universal Registration Document 2019](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/03/28/2-59-56/2019-report-cover.jpg?itok=tUy4e0Dc)\n\n[Universal Registration Document 2019](/static-files/1f571870-283b-4b14-bca9-77a87a8c2062 \"2020-001000.pdf\") 5.7 MB\n\n[Universal Registration Document 2019 Amendment](/static-files/eb52c2f4-c389-4331-bef1-0fdece099387 \"2020-0339-A01-00 - amendment.pdf\") 3.1 MB\n\n[Universal Registration Document 2019 Amendment 2](/static-files/e73fc6a4-1654-41fa-a842-237a9e14defa \"2020-0339-A02-00 - amendment.pdf\") 730.5 KB\n\n![Annual Report 2018](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/03/29/4-32-59/2018-report-cover.jpg?itok=3sdAD_BS)\n\n[Annual Report 2018](/static-files/b6ca6ce1-3c34-4e3c-8a42-c20207acac01 \"2019-001800.pdf\") 2.3 MB\n\n![Annual Report 2016](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/03/29/5-03-13/2016-report-cover.jpg?itok=sh2nI9G3)\n\n[Annual Report 2016](/static-files/c80388f5-9f52-467e-84c5-d3ee353135a2 \"2017-047000.pdf\") 8.2 MB\n\n![Annual Report 2015](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/03/29/5-12-17/2015-report-cover.jpg?itok=XVE3BLUe)\n\n[Annual Report 2015](/static-files/36a38c5f-d3d3-4a0b-997b-b24a2584046e \"2016-073200.pdf\") 5.5 MB\n\n[Annual Report 2015 Amendment](/static-files/48834b92-1f93-4ad5-8578-0e4468e586eb \"2016-0732-A01-00 - amendment.pdf\") 8 MB\n\n![](/sites/g/files/knoqqb86031/themes/site/client_site/dist/images/default-cover.jpg)\n\n[Annual Report 2014](/static-files/f20a995a-37bd-456b-9d75-473b04fae6b1 \"2016-000100.pdf\") 6.2 MB\n\n![](/sites/g/files/knoqqb86031/themes/site/client_site/dist/images/default-cover.jpg)\n\n[Annual Report 2013](/static-files/4be54b13-a0c3-4a94-b0e4-9bb12b004889 \"2014-007100.pdf\") 5.9 MB\n\n![](/sites/g/files/knoqqb86031/themes/site/client_site/dist/images/default-cover.jpg)\n\n[Annual Report 2012](/static-files/18736680-1f41-4f4d-8478-daef9501fb7f \"2014-000200.pdf\") 5.5 MB\n\n![](/sites/g/files/knoqqb86031/themes/site/client_site/dist/images/default-cover.jpg)\n\n[Annual Report 2011](/static-files/21c3d514-80b1-482a-9c61-c0ddf7aa9bd6 \"2012-004300.pdf\") 4.2 MB\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.nanobiotix.com/financial-information/quarterly-results",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Quarterly Results\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\n[Show All](#)\n\n## 2024\n\n### H1\n\n  * [Press release](/static-files/73d416c5-d0e7-4e17-af46-4ba8540918a0 \"20240918-Nanobiotix_H1_24_Financial_Results-EN.pdf\") 309.1 KB\n\n\n\n\n### Q1\n\n  * [Press Release](/static-files/e1c8dba0-5bf7-4f53-8631-636bebe80106 \"20240522-Nanobiotix_Press_Release-1Q_2024_Earnings-EN.pdf\") 129.3 KB\n\n\n\n\n## 2023\n\n### Annual\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/assets/2024/04/24/17-33-07/20240424-NBTX-PR-FY2023_Financial_Results-EN.pdf \"20240424-NBTX-PR-FY2023_Financial_Results-EN.pdf\") 335.7 KB\n\n  * [Webcast](/events/event-details/full-year-2023-financial-results)\n\n\n\n\n### H1\n\n  * [Press release](/news-releases/news-release-details/nanobiotix-provides-business-update-and-financial-results-first)\n\n  * [Webcast](/events/event-details/half-year-2023-financial-results)\n\n\n\n\n### Q3\n\n  * [Press release](/news-releases/news-release-details/nanobiotix-provides-third-quarter-2023-operational-and-financial)\n\n  * [Webcast](/events/event-details/third-quarter-2023-financial-results)\n\n\n\n\n### Q1\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-first-quarter-2023-operational-and-financial)\n\n\n\n\n## 2022\n\n### Annual\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-business-update-and-reports-full-year-2022)\n\n  * [Webcast](/events/event-details/full-year-2022-financial-results)\n\n\n\n\n### H1\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-business-update-and-reports-financial-0)\n\n  * [Webcast](/events/event-details/half-year-2022-financial-results)\n\n\n\n\n### Q3\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-third-quarter-2022-operational-and-financial)\n\n  * [Webcast](/events/event-details/third-quarter-2022-financial-results-november-9-2022)\n\n\n\n\n### Q1\n\n  * [Press Release](/news-releases/news-release-details/correcting-and-replacing-nanobiotix-provides-first-quarter)\n\n  * [Webcast](/events/event-details/first-quarter-2021-corporate-and-financial-update)\n\n\n\n\n## 2021\n\n### Annual\n\n  * [Webcast](/events/event-details/2021-full-year-corporate-and-financial-update)\n\n\n\n\n### H1\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-business-update-and-reports-financial)\n\n\n\n\n### Q3\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-third-quarter-operational-and-financial)\n\n\n\n\n### Q2\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-provides-second-quarter-operational-and-financial)\n\n\n\n\n### Q1\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-announces-first-quarter-operational-and-financial)\n\n\n\n\n## 2020\n\n### Annual\n\n  * [Press Release](/news-releases/news-release-details/nanobiotix-reports-full-year-2020-financial-results-and)\n\n\n\n\n### H1\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/4-54-06/Nanobiotix%20announces%20half-year%20financial%20statements%20as%20at%20June%2030%2C%202020.pdf \"Nanobiotix announces half-year financial statements as at June 30, 2020.pdf\") 256.5 KB\n\n\n\n\n### Q3\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/4-46-33/Nanobiotix%20announces%20third%20quarter%202020%20revenue.pdf \"Nanobiotix announces third quarter 2020 revenue.pdf\") 164.7 KB\n\n\n\n\n### Q2\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/5-40-14/Nanobiotix%20announces%20revenue%20for%20second%20quarter%202020%20and%20first%20half%20year%202020.pdf \"Nanobiotix announces revenue for second quarter 2020 and first half year 2020.pdf\") 201.9 KB\n\n\n\n\n### Q1\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/5-50-58/Nanobiotix%20announces%20first%20quarter%202020%20revenues.pdf \"Nanobiotix announces first quarter 2020 revenues.pdf\") 175 KB\n\n\n\n\n## 2019\n\n### Annual\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-39-03/Nanobiotix%202019%20Annual%20results.pdf \"Nanobiotix 2019 Annual results.pdf\") 458.6 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-38-26/Financial%20_%20Nanobiotix%20announces%20half%20year%20financial%20statements%20of%20june%2030%2C%202019.pdf \"Financial _ Nanobiotix announces half year financial statements of june 30, 2019.pdf\") 325.3 KB\n\n\n\n\n### Q4\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-35-47/Nanobiotix%202019%20Q4%20and%20annual%20revenues.pdf \"Nanobiotix 2019 Q4 and annual revenues.pdf\") 176.7 KB\n\n\n\n\n### Q3\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-35-12/Financial%20_%20Nanobiotix%20announces%20third%20quarter%202019%20revenue.pdf \"Financial _ Nanobiotix announces third quarter 2019 revenue.pdf\") 162.7 KB\n\n\n\n\n### Q2\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-34-39/Financial%20_%20Nanobiotix%20announces%20second%20quarter%202019%20revenue.pdf \"Financial _ Nanobiotix announces second quarter 2019 revenue.pdf\") 273.6 KB\n\n\n\n\n### Q1\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/5-34-03/Financial%20_%20Nanobiotix%20announces%20first%20quarter%202019%20revenue.pdf \"Financial _ Nanobiotix announces first quarter 2019 revenue.pdf\") 267.1 KB\n\n\n\n\n## 2018\n\n### Annual\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-51-12/Financial%20_%20Nanobiotix%202018%20Annual%20Results.pdf \"Financial _ Nanobiotix 2018 Annual Results.pdf\") 573.6 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/6-56-16/Financial%20_%20Nanobiotix%202018%20Annual%20Results.pdf \"Financial _ Nanobiotix 2018 Annual Results.pdf\") 573.6 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-50-33/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%20June%2030%2C%202018.pdf \"Financial _ Nanobiotix half year results for the six months ended June 30, 2018.pdf\") 341.7 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-19-55/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%20June%2030%2C%202018.pdf \"Financial _ Nanobiotix half year results for the six months ended June 30, 2018.pdf\") 341.7 KB\n\n\n\n\n### Q4\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-50-13/Financial%20_%20Nanobiotix%202018%20Q4%20and%20annual%20revenues.pdf \"Financial _ Nanobiotix 2018 Q4 and annual revenues.pdf\") 301.6 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/6-57-55/Financial%20_%20Nanobiotix%202018%20Q4%20and%20annual%20revenues.pdf \"Financial _ Nanobiotix 2018 Q4 and annual revenues.pdf\") 301.6 KB\n\n\n\n\n### Q3\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-49-49/Financial%20_%20Nanobiotix%20revenues%20for%20the%203rd%20quarter%20of%202018.pdf \"Financial _ Nanobiotix revenues for the 3rd quarter of 2018.pdf\") 304.9 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-13-45/Financial%20_%20Nanobiotix%20revenues%20for%20the%203rd%20quarter%20of%202018.pdf \"Financial _ Nanobiotix revenues for the 3rd quarter of 2018.pdf\") 304.9 KB\n\n\n\n\n### Q2\n\n  * [Revenues](/static-files/c4d21484-ce28-45f9-8e83-0a7c12f2a64d \"Finance _ Chiffre d’affaires du deuxième trimestre 2018.pdf\") 289.3 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-22-36/Financial%20_%20NANOBIOTIX%20revenue%20for%20the%202nd%20quarter%20of%202018.pdf \"Financial _ NANOBIOTIX revenue for the 2nd quarter of 2018.pdf\") 284.3 KB\n\n\n\n\n### Q1\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-49-18/Financial%20_%20NANOBIOTIX%20revenue%20for%20the%201st%20quarter%20of%202018.pdf \"Financial _ NANOBIOTIX revenue for the 1st quarter of 2018.pdf\") 262.1 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-26-41/Financial%20_%20NANOBIOTIX%20revenue%20for%20the%201st%20quarter%20of%202018.pdf \"Financial _ NANOBIOTIX revenue for the 1st quarter of 2018.pdf\") 262.1 KB\n\n\n\n\n## 2017\n\n### Annual\n\n  * [Results](/static-files/825440ff-95f8-4ae6-9f20-b4784ac3009a \"Financial _ Nanobiotix 2017 Annual Results.pdf\") 490.2 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-31-52/Financial%20_%20Nanobiotix%202017%20Annual%20Results.pdf \"Financial _ Nanobiotix 2017 Annual Results.pdf\") 490.2 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-26-46/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%2030%20June%202017.pdf \"Financial _ Nanobiotix half year results for the six months ended 30 June 2017.pdf\") 494.8 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/11-25-04/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%2030%20June%202017.pdf \"Financial _ Nanobiotix half year results for the six months ended 30 June 2017.pdf\") 494.8 KB\n\n\n\n\n### Q4\n\n  * [Revenues](/static-files/1a40df36-0a7e-4d78-a519-e4c3ab3c87ef \"Financial _ Nanobiotix 2017 Q4 and annual revenues.pdf\") 442.9 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/7-32-41/Financial%20_%20Nanobiotix%202017%20Q4%20and%20annual%20revenues.pdf \"Financial _ Nanobiotix 2017 Q4 and annual revenues.pdf\") 442.9 KB\n\n\n\n\n### Q3\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-24-51/Financial%20_%20Nanobiotix%20revenues%20for%20the%203rd%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenues for the 3rd quarter of 2017.pdf\") 420 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/11-11-56/Financial%20_%20Nanobiotix%20revenues%20for%20the%203rd%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenues for the 3rd quarter of 2017.pdf\") 420 KB\n\n\n\n\n### Q2\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-23-53/Financial%20_%20Nanobiotix%20revenues%20for%20the%202nd%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenues for the 2nd quarter of 2017.pdf\") 418.7 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/06/11-26-33/Financial%20_%20Nanobiotix%20revenues%20for%20the%202nd%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenues for the 2nd quarter of 2017.pdf\") 418.7 KB\n\n\n\n\n### Q1\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/22/4-23-10/Financial%20_%20Nanobiotix%20revenue%20for%20the%201st%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenue for the 1st quarter of 2017.pdf\") 418.8 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-05-12/Financial%20_%20Nanobiotix%20revenue%20for%20the%201st%20quarter%20of%202017.pdf \"Financial _ Nanobiotix revenue for the 1st quarter of 2017.pdf\") 418.8 KB\n\n\n\n\n## 2016\n\n### Annual\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-14-49/Financial%20_%20Nanobiotix_%202016%20Annual%20Results.pdf \"Financial _ Nanobiotix_ 2016 Annual Results.pdf\") 475 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-06-12/Financial%20_%20Nanobiotix_%202016%20Annual%20Results.pdf \"Financial _ Nanobiotix_ 2016 Annual Results.pdf\") 475 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-13-54/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%2030%20June%202016.pdf \"Financial _ Nanobiotix half year results for the six months ended 30 June 2016.pdf\") 502.3 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-29-54/Financial%20_%20Nanobiotix%20half%20year%20results%20for%20the%20six%20months%20ended%2030%20June%202016.pdf \"Financial _ Nanobiotix half year results for the six months ended 30 June 2016.pdf\") 502.3 KB\n\n\n\n\n### Q4\n\n  * [Revenue](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-13-24/Financial%20_%20Nanobiotix%202016%20Q4%20and%20annual%20revenues.pdf \"Financial _ Nanobiotix 2016 Q4 and annual revenues.pdf\") 426.6 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-13-05/Financial%20_%20Nanobiotix%202016%20Q4%20and%20annual%20revenues.pdf \"Financial _ Nanobiotix 2016 Q4 and annual revenues.pdf\") 426.6 KB\n\n\n\n\n### Q3\n\n  * [Revenue](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-13-02/Financial%20_%20Nanobiotix%20revenue%20for%20Q3%202016.pdf \"Financial _ Nanobiotix revenue for Q3 2016.pdf\") 430 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-22-50/Financial%20_%20Nanobiotix%20revenue%20for%20Q3%202016.pdf \"Financial _ Nanobiotix revenue for Q3 2016.pdf\") 430 KB\n\n\n\n\n### Q2\n\n  * [Revenue](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-12-09/Financial%20_%20Nanobiotix%20revenue%20for%20Q2%202016.pdf \"Financial _ Nanobiotix revenue for Q2 2016.pdf\") 410.7 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-30-54/Financial%20_%20Nanobiotix%20revenue%20for%20Q2%202016.pdf \"Financial _ Nanobiotix revenue for Q2 2016.pdf\") 410.7 KB\n\n\n\n\n### Q1\n\n  * [Revenue](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/11-11-50/Financial%20_%20Revenue%20for%20the%201st%20quarter%20of%202016.pdf \"Financial _ Revenue for the 1st quarter of 2016.pdf\") 456.7 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-46-39/Financial%20_%20Revenue%20for%20the%201st%20quarter%20of%202016.pdf \"Financial _ Revenue for the 1st quarter of 2016.pdf\") 456.7 KB\n\n\n\n\n## 2015\n\n### Annual\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/10-51-30/Financial%20_%20Nanobiotix%202015%20Annual%20Results.pdf \"Financial _ Nanobiotix 2015 Annual Results.pdf\") 484.6 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-47-54/Financial%20_%20Nanobiotix%202015%20Annual%20Results.pdf \"Financial _ Nanobiotix 2015 Annual Results.pdf\") 484.6 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/10-51-22/Financial%20_%20Nanobiotix%20Half%20Year%20Results%20for%20the%20period%20ended%2030%20June%202015.pdf \"Financial _ Nanobiotix Half Year Results for the period ended 30 June 2015.pdf\") 607.2 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/5-00-10/Financial%20_%20Nanobiotix%20Half%20Year%20Results%20for%20the%20period%20ended%2030%20June%202015.pdf \"Financial _ Nanobiotix Half Year Results for the period ended 30 June 2015.pdf\") 607.2 KB\n\n\n\n\n### Q3\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/10-51-13/Financial%20_%20Nanobiotix%20Revenue%20Q3%202015.pdf \"Financial _ Nanobiotix Revenue Q3 2015.pdf\") 110.5 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/4-52-12/Financial%20_%20Nanobiotix%20Revenue%20Q3%202015.pdf \"Financial _ Nanobiotix Revenue Q3 2015.pdf\") 110.5 KB\n\n\n\n\n### Q2\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/10-51-05/Financial%20_%20Nanobiotix%20Revenue%20Q2%202015.pdf \"Financial _ Nanobiotix Revenue Q2 2015.pdf\") 104.7 KB\n\n  * [Press Release](/static-files/3b9a8752-5528-4d12-a365-b12b4e73da61 \"Financial _ Nanobiotix Revenue Q2 2015.pdf\") 104.7 KB\n\n\n\n\n### Q1\n\n  * [Revenues](/static-files/907f5934-6ff0-4907-8b8c-e2be6249ab4d \"Financial _ Nanobiotix Revenue Q1 2015.pdf\") 103.9 KB\n\n  * [Press Release](/static-files/03024966-7505-4150-9f4f-4f3e7311f45b \"Financial _ Nanobiotix Revenue Q1 2015.pdf\") 103.9 KB\n\n\n\n\n## 2014\n\n### Annual\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-59-30/Financial%20_%20Nanobiotix%202014%20Annual%20Results.pdf \"Financial _ Nanobiotix 2014 Annual Results.pdf\") 110.9 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/5-08-09/Financial%20_%20Nanobiotix%202014%20Annual%20Results.pdf \"Financial _ Nanobiotix 2014 Annual Results.pdf\") 110.9 KB\n\n\n\n\n### H1\n\n  * [Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-42-16/Financial%20_%20Nanobiotix%20Half%20year%20Results%20for%20the%20period%20ended%2030%20june%202014.pdf \"Financial _ Nanobiotix Half year Results for the period ended 30 june 2014.pdf\") 135.2 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/6-38-28/Financial%20_%20Nanobiotix%20Half%20year%20Results%20for%20the%20period%20ended%2030%20june%202014.pdf \"Financial _ Nanobiotix Half year Results for the period ended 30 june 2014.pdf\") 135.2 KB\n\n\n\n\n### Q4\n\n  * [Q4 and Annual Revenues](/static-files/66072b44-c57d-47e8-a0b2-b4eedd39312b \"Financial _ Nanobiotix 2014 Q4 and annual revenues.pdf\") 108.9 KB\n\n  * [Press Release](/static-files/d04bc5a5-483c-49bd-b6fd-6c4d7df54b72 \"Financial _ Nanobiotix 2014 Q4 and annual revenues.pdf\") 108.9 KB\n\n\n\n\n### Q3\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-40-46/Financial%20_%20Nanobiotix%202014%20Q3%20Revenues.pdf \"Financial _ Nanobiotix 2014 Q3 Revenues.pdf\") 104.1 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/6-30-39/Financial%20_%20Nanobiotix%202014%20Q3%20Revenues.pdf \"Financial _ Nanobiotix 2014 Q3 Revenues.pdf\") 104.1 KB\n\n\n\n\n### Q2\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-40-14/Financial%20_%20Nanobiotix%202014%20Q2%20Revenues.pdf \"Financial _ Nanobiotix 2014 Q2 Revenues.pdf\") 97.1 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/6-40-36/Financial%20_%20Nanobiotix%202014%20Q2%20Revenues.pdf \"Financial _ Nanobiotix 2014 Q2 Revenues.pdf\") 97.1 KB\n\n\n\n\n### Q1\n\n  * [Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-39-43/Financial%20_%20Nanobiotix%20Revenue%20Q1%202014%20and%20new%20composition%20shareholding.pdf \"Financial _ Nanobiotix Revenue Q1 2014 and new composition shareholding.pdf\") 149.3 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/6-44-15/Financial%20_%20Nanobiotix%20Revenue%20Q1%202014%20and%20new%20composition%20shareholding.pdf \"Financial _ Nanobiotix Revenue Q1 2014 and new composition shareholding.pdf\") 149.3 KB\n\n\n\n\n## 2013\n\n### Annual\n\n  * [2013 Annual Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-17-59/Financial%20_%20Nanobiotix%202013%20Annual%20Results.pdf \"Financial _ Nanobiotix 2013 Annual Results.pdf\") 111 KB\n\n  * [2013 Annual Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-17-34/Financial%20_%20Nanobiotix%202013%20annual%20revenues.pdf \"Financial _ Nanobiotix 2013 annual revenues.pdf\") 427.4 KB\n\n  * [Press Release Annual Revenues](/system/files-encrypted/nasdaq_kms/news/2022/01/07/8-46-53/Financial%20_%20Nanobiotix%202013%20annual%20revenues.pdf \"Financial _ Nanobiotix 2013 annual revenues.pdf\") 427.4 KB\n\n  * [Press Release Annual Results](/system/files-encrypted/nasdaq_kms/news/2022/01/07/6-47-08/Financial%20_%20Nanobiotix%202013%20Annual%20Results.pdf \"Financial _ Nanobiotix 2013 Annual Results.pdf\") 111 KB\n\n\n\n\n### H1\n\n  * [2013 HY Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-16-56/Financial%20_%20Nanobiotix%20Half%20Year%20Results%20for%20the%20period%20ended%2030%20June%202013.pdf \"Financial _ Nanobiotix Half Year Results for the period ended 30 June 2013.pdf\") 125.3 KB\n\n\n\n\n### Q3\n\n  * [2013 Q3 Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-15-28/Financial%20_%20Nanobiotix%20Q3%20Revenue%202013.pdf \"Financial _ Nanobiotix Q3 Revenue 2013.pdf\") 110.9 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/8-57-04/Financial%20_%20Nanobiotix%20Q3%20Revenue%202013.pdf \"Financial _ Nanobiotix Q3 Revenue 2013.pdf\") 110.9 KB\n\n\n\n\n### Q2\n\n  * [2013 Q2 Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-14-44/Financial%20_%20Nanobiotix%202013%20Q2%20revenue.pdf \"Financial _ Nanobiotix 2013 Q2 revenue.pdf\") 173.5 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/10-11-47/Financial%20_%20Nanobiotix%202013%20Q2%20revenue.pdf \"Financial _ Nanobiotix 2013 Q2 revenue.pdf\") 173.5 KB\n\n\n\n\n### Q1\n\n  * [2013 Q1 Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/9-14-22/Financial%20_%20Nanobiotix%202013%20Q1%20revenues.pdf \"Financial _ Nanobiotix 2013 Q1 revenues.pdf\") 445.4 KB\n\n  * [Press Release](/system/files-encrypted/nasdaq_kms/news/2022/01/07/10-17-41/Financial%20_%20Nanobiotix%202013%20Q1%20revenues.pdf \"Financial _ Nanobiotix 2013 Q1 revenues.pdf\") 445.4 KB\n\n\n\n\n## 2012\n\n### Annual\n\n  * [2012 Annual Results](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/8-57-14/Financial%20_%20Nanobiotix%202012%20Annual%20Results.pdf \"Financial _ Nanobiotix 2012 Annual Results.pdf\") 99.9 KB\n\n  * [2012 Revenues](/system/files-encrypted/nasdaq_kms/assets/2022/03/21/8-56-20/Financial%20_%20Nanobiotix%202012%20revenues.pdf \"Financial _ Nanobiotix 2012 revenues.pdf\") 475.7 KB\n\n\n\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        },
        {
          "title": "AMF Regulated Information",
          "url": "https://ir.nanobiotix.com/financial-information/amf-regulated-information",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# AMF Regulated Information\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\nYear All202420232022202120202019201820162015201420132012\n\n2024\n\nSep 18, 2024\n\nRapport Financier Semestriel \n\n[Download EN](/static-files/41c5fe90-a19d-45d7-b46a-a4e6330b0fc1 \"Nanobiotix+-+AMF+-+RFS+2024.pdf\") 518.9 KB\n\nApr 24, 2024\n\n2023 Universal Registration Document \n\n[Download EN](/static-files/89b140f1-3c15-4ee4-beec-8633f9f41c56 \"Nanobiotix - AMF - URD 2023 - vdef.pdf\") 14.8 MB\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n\n![Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=e81fc3ad-8c8d-42f5-ae2d-a2b6fa77dc61)\n"
        },
        {
          "title": "AGM",
          "url": "https://ir.nanobiotix.com/financial-information/annual-general-meeting",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Annual General Meetings\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\nYear All202420232022202120202019201820172016201520142013\n\n2024\n\nMay 29, 2024\n\nVoting Results Shareholders Meeting of May 28 2024 \n\n[Download EN](/static-files/9427c093-0463-46f8-9e06-410f94b04e9a \"NANOBIOTIX Voting Results Shareholders Meeting of May 28 2024.pdf\") 133 KB\n\nMay 29, 2024\n\nMinutes of the General Meeting (French only) – AGM May 28, 2024 \n\n[Download FR](/static-files/c35143aa-bf20-434f-b199-4d27104ee498 \"NANOBIOTIX AGM 28 Mai 2024 - Minutes du PV.pdf\") 3.3 MB\n\nMay 13, 2024\n\nNotice of meeting published in the French Bulletin des Annonces Légales Obligatoires of May 13, 2024 (French only) \n\n[Download FR](/static-files/705077aa-83cd-43b1-8226-c522175bc0d0 \"NANOBIOTIX AGM 28 mai 2024 - avis de convocation.pdf\") 397.6 KB\n\nMay 07, 2024\n\nNumber of shares outstanding and voting rights (in French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/94feedce-15bf-416b-9c7e-5c7244105a6d \"NANOBIOTIX actions et droits de vote au 22 04 2024.pdf\") 177.5 KB\n\nMay 07, 2024\n\nStatutory auditors’ reports to the Annual General Shareholders’ Meeting May 2024 (French only) \n\n[Download FR](/static-files/97097baf-4b99-4556-9d67-86ccc1646105 \"Rapports des commissaires aux comptes à l’Assemblée Générale Annuelle Mai 2024.zip\") 3.5 MB\n\nMay 07, 2024\n\nStatutory auditors’ report on the consolidated financial statements 2023 (in French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/4dae57f3-c44f-4b98-80ad-e54205a971d2 \"Nanobiotix-Rapports Comptes Annuels GT & EY.pdf\") 1.1 MB\n\nMay 07, 2024\n\nNotice ADSs agenda and summaries of resolutions – shareholders’ general meeting May 28, 2024 \n\n[Download EN](/static-files/70b5b6fb-d743-4169-bb08-c66188d19aff \"Nanobiotix notice_ADSs.pdf\") 129.5 KB\n\nMay 07, 2024\n\nTotal amount, certified as exact by the statutory auditors, of remunerations paid to the five highest-paid people (French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/bc14b3c2-3aca-4ef0-8660-6dc4634d29da \"Nanobiotix Attestation remuneration globale aux 5 personnes les mieux rémunérées GT EY.pdf\") 451.9 KB\n\nMay 07, 2024\n\nStatutory auditors’ report on related party agreements 2023 (in French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/504e7e34-a681-4e16-a85b-a6bdf1761e6d \"Nanobiotix- Rapport conventions réglementées GT EY.pdf\") 358.5 KB\n\nMay 07, 2024\n\nBrochure sharehloders’ meeting May 28, 2024, including full agenda (in French only) \n\n[Download FR](/static-files/8a7e3e9a-e8c9-459e-a8f9-613698c48c45 \"Nanobiotix Convocation AGM 28 mai 2024 - brochure \\(résolutions-formulaires\\).pdf\") 1.5 MB\n\nMay 07, 2024\n\nNotice RADSs agenda and summaries of resolutions – shareholders’ general meeting May 28, 2024 \n\n[Download EN](/static-files/4c57b769-3b34-42c6-a7aa-329ab7044c57 \"Nanobiotix notice_RADSs.pdf\") 132.8 KB\n\nMay 07, 2024\n\nStatutory auditors’ report on the consolidated financial statements 2023 – (in French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/2e9b8906-e140-41d2-9757-aa41bbfa3c59 \"Nanobiotix-Rapports Comptes Consolidés GT & EY.pdf\") 1.6 MB\n\nMay 07, 2024\n\nURD 2023 including management report and financial statements (in French only) - AGM May 28, 2024 \n\n[Download FR](/static-files/b104476f-efa1-41a9-bb7c-70cb39c8463e \"Nanobiotix - AMF - URD 2023 - vdef.pdf\") 14.8 MB\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n\n![Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=e81fc3ad-8c8d-42f5-ae2d-a2b6fa77dc61)\n"
        }
      ]
    },
    {
      "section_name": "Shareholder Services",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://ir.nanobiotix.com/shareholder-services/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Investor FAQs\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\n[Show All](#)\n\nPress space to expand and collapse this section\n\nWhich stock exchanges is Nanobiotix listed on? \n\nNANOBIOTIX’s ordinary shares are listed on the Euronext Paris Stock Exchange under the symbol “NANO” NANOBIOTIX’s ordinary shares, in the form of American Depositary Shares, or ADSs, are listed on the Nasdaq Global Select Market under the symbol “NBTX” and held by a depository bank, Citibank N.A. Each ADS represents the right to receive one ordinary share.\n\nPress space to expand and collapse this section\n\nHow do I contact NANOBIOTIX’s Depositary Bank? \n\nCitibank, N.A. has agreed to act as the depositary for the American Depositary Shares. Citibank’s depositary offices are located at 388 Greenwich Street, New York, New York 10013. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank Europe Plc Dublin (CEP), located at EGSP 186, 1 North Wall Quay, Dublin 1 Ireland. \n\nPress space to expand and collapse this section\n\nWhat does a depositary bank do? \n\nA depositary is a bank that facilitates cross-border trading of an issuer’s shares. Among other things, depositary banks provide ADS issuance and cancellation services, and associated stock transfer services such as maintaining the register of holders, and providing annual meeting services. \n\nPress space to expand and collapse this section\n\nCan non-U.S. shareholders invest in NANOBIOTIX’s ADSs?\n\nYes, it is permissible for Euronext Paris shareholders to purchase ADSs directly or to convert their Euronext Paris ordinary shares into ADSs. We would advise that Paris shareholders seek advice from a broker and/or tax adviser. \n\nPress space to expand and collapse this section\n\nAre holders of ADSs entitled to vote at NANOBIOTIX’s annual general meeting? \n\nHolders of ADSs may authorize Citibank, N.A., NANOBIOTIX’s Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADSs. \n\nPress space to expand and collapse this section\n\nHow can I keep up to date with latest developments at NANOBIOTIX? \n\nYou can register to receive updates announced by NANOBIOTIX by submitting your email address in Email Alerts on the Investor Relations section of our website. Alternatively you can send an email to investor relations requesting to be notified of any new updates announced at investors@nanobiotix.com. \n\nPress space to expand and collapse this section\n\nWho is NANOBIOTIX’s independent registered public accounting firm? \n\nERNST & YOUNG et Autres Tour First 2 Place des Saisons 92400 Courbevoie France \n\nGRANT THORNTON 29 Rue du Pont 92200 Neuilly-sur-Seine France \n\nPress space to expand and collapse this section\n\nHow do I obtain a copy of the company’s annual report? \n\nNANOBIOTIX’s annual reports, interim report and press releases can be downloaded from NANOBIOTIX’s website. To receive a hard copy of NANOBIOTIX’s latest annual report, please contact us by emailing investors@nanobiotix.com. \n\nPress space to expand and collapse this section\n\nWhen is the company’s financial year end? \n\nNANOBIOTIX’s financial year ends on 31 December. \n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        },
        {
          "title": "Contact IR",
          "url": "https://ir.nanobiotix.com/shareholder-services/contact-ir",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Contact IR\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\nNanobiotix SA 60 rue de Wattignies, 75012 Paris France +33 (0)1 40 26 04 70\n\nNanobiotix Corp. 245 Main Street 3rd floor Cambridge, MA02142 United States Tél : +1 (617) 7 12-15 68 Fax: +33 (0)1 40 26 04 44\n\nCraig West SVP, Investor Relations investors@nanobiotix.com\n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Governance Overview",
          "url": "https://ir.nanobiotix.com/corporate-governance/governance-overview",
          "content": "[Skip to content](#lfg-main-content)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\n[![Nanobiotix logo](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/nanobiotix_logo.svg)](https://www.nanobiotix.com/)\n\nMain Menu\n\n# Governance Overview\n\n![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investors-hero-type-background.png) ![investors hero background type](/sites/g/files/knoqqb86031/themes/site/client_site/dist/wp-content/uploads/2023/05/investisseurs-type-texture-hero-FR.png)\n\n## **Corporate Governance Practices**\n\nAs a French société anonyme listed on the regulated market of Euronext in Paris, we are subject to various corporate governance requirements under French law. In addition, as a foreign private issuer listed on the Nasdaq Global Select Market, we are subject to the Nasdaq corporate governance listing standards. \n\nWe have a two-tier corporate governance system consisting of an executive board (Directoire), which is responsible for managing the Company and a supervisory board (Conseil de Surveillance), which oversees the executive board. \n\n## Executive Board\n\nWe are managed by an executive board under the control of a supervisory board. The members of the executive board determine the broad lines of our business activities and ensure their implementation.\n\n## Supervisory Board\n\nThe members of the supervisory board exercise control over the management of the executive board. The supervisory board operates pursuant to a separate charter adopted by its members on March 18, 2019.\n\nWe currently have four members of the supervisory board.\n\n## Governance Documents\n\nWe have adopted a Code of Business Conduct and Ethics (“Code of Conduct”) that is applicable to all of our, and our subsidiaries', employees, executive board members and supervisory board members.\n\nOur supervisory board has established an audit committee and an appointments and compensation committee, each of which operates pursuant to a separate charter.\n\nOur audit committee monitors the questions relating to the processing and control of accounting and financial information. To this end, it ensures the quality of our internal controls and the reliability of information provided to shareholders and financial markets.\n\nOur appointments and compensation committee provides recommendations and proposals to our executive and supervisory board members on the composition and compensation policies of our executive and supervisory boards, and also prepares any related reports to be provided by us. \n\n## Governance Documents\n\n[Code of Business Conduct and Ethics](/static-files/fd697ea5-17b6-4536-bfe2-5539e84305f3)\n\n## Committee Charters\n\n[Appointments and Compensation Committee Charter](/static-files/67d7a9e4-d969-4b50-8524-b8e2b3ad440d)\n\n[Audit Committee Charter](/static-files/0507580f-3f02-46c9-911c-8cc46cd3e256)\n\n**For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.**\n\n[ CONTACT US ](/shareholder-services/contact-ir)\n"
        }
      ]
    }
  ]
}